Ginkgo Bioworks Holdings ROA 2020-2022 | DNA

Current and historical return on assets (ROA) values for Ginkgo Bioworks Holdings (DNA) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Ginkgo Bioworks Holdings ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-12-31 $-2.11B $2.54B -99.55%
2022-09-30 $-3.53B $1.87B -176.63%
2022-06-30 $-2.96B $1.99B -143.24%
2022-03-31 $-2.35B $2.06B -117.31%
2021-12-31 $-1.83B $2.07B -95.41%
2021-06-30 $-0.15B $1.73B -17.83%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.549B $0.478B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $140.576B 8.70
GSK (GSK) United Kingdom $75.923B 9.52
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.436B 19.34
Arcus Biosciences (RCUS) United States $1.194B 0.00
Biohaven (BHVN) United States $0.913B 0.00
Emergent Biosolutions (EBS) United States $0.394B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
Enzo Biochem (ENZ) United States $0.106B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.012B 0.00